- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03225820
Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
Study Overview
Status
Conditions
Detailed Description
This study aims to determine whether preemptively obtained pharmacogenomic information can be delivered and utilized at the point-of-care across multiple institutions specifically in African American patients at risk for minority health disparities. The investigators have chosen the high-stakes, rapid-paced setting of inpatient medicine for this implementation study. The investigators seek to examine whether the availability of pharmacogenomic information improves prescribing.
The investigators will enroll adults at one of three institutions, The University of Chicago, University of Illinois at Chicago, and Northwestern University. During an initial (enrollment) hospital inpatient encounter, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Patients will also be targeted for enrollment who are highly likely to initiate future warfarin therapy. Patients will be recruited to two primary cohorts. In the feasibility cohort, all patients will have their actionable pharmacogenomic results (with decision support) available to inpatient treating physicians for the duration of the study, once genotyping is completed, via the Genomic Prescribing System (GPS). Physicians and pharmacists will be individually approached for enrollment through a process of direct stakeholder engagement and informed consent. Participating providers will give permission for their medication decisions to be analyzed. Providers will never be instructed how to practice nor how to prescribe, and it is their choice whether or not to use GPS. GPS accession, use, and all medications prescribed throughout the admission will be passively recorded by the research team, for all patients, and an analysis of the impact of GPS results and decision-supports will be performed.
For the African American warfarin cohort, patients newly-starting warfarin will be enrolled at the time of new warfarin initiation and then randomized such that their treating physicians and pharmacists either have access to African American-specific warfarin dosing guidance via GPS, or not. The frequency of unfavorable (high-risk) scenarios related to warfarin-related clinical outcomes will be examined in each group.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Not yet recruiting
- Northwestern University
-
Contact:
- Kevin O'Leary, MD
- Phone Number: 312-926-2537
-
Chicago, Illinois, United States, 60607
- Recruiting
- The University of Illinois at Chicago
-
Contact:
- Peter O'Donnell, MD
- Phone Number: 773-702-7564
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must be at least 18 years of age.
- Patients must self-identify as African American
Exclusion Criteria:
- Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
- Patients with known active or prior leukemia.
- Inability to understand and give informed consent to participate.
- For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance <30 mL/min34.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
---|
Overall Pharmacogenomics
All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance. NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits. |
Warfarin Sub-Study
All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance. NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Geonomic Prescribing System (GPS) use by physicians and pharmacists
Time Frame: Up to 5 years
|
To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery for African Americans in the inpatient setting across multiple institutions by determining the frequency of Genomic Prescribing System (GPS) use by physicians and pharmacists caring for self-identified African American patients.
|
Up to 5 years
|
Number of improved clinical outcomes
Time Frame: Up to 5 years
|
To determine whether African-American-specific pharmacogenomic and clinical dosing guidance results in improved clinical outcomes related to warfarin compared to dosing without such guidance.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of use of pharmacogenomically-identified higher-risk drugs (increased pharmacogenomic risk)
Time Frame: 5 years
|
To determine the rate of use of pharmacogenomically-identified higher-risk drugs (increased pharmacogenomic risk) in patients for whom pharmacogenomic results are available, comparing specifically patients whose providers access GPS during an admission versus when their providers do not.
|
5 years
|
Number of specific pharmacogenomically-informed adverse drug events
Time Frame: 5 years
|
To determine the occurrence of specific pharmacogenomically-informed adverse drug events in both arms.
|
5 years
|
Quantitative survey responses from pharmacists' and physicians'
Time Frame: After the date of discharge for the patient, not to exceed 5 years.
|
To determine pharmacists' and physicians' knowledge, attitudes and perceptions of prescribing including pharmacogenomic-informed prescribing by providing a survey for the appropriate individuals to complete.
|
After the date of discharge for the patient, not to exceed 5 years.
|
Quantitative survey responses from patients
Time Frame: After the date of discharge for the patient, not to exceed 5 years.
|
To determine whether differences in patient-reported satisfaction and adherence likelihood are observable for patients whose providers access and use pharmacogenomic information by providing a survey for the appropriate individuals to complete.
|
After the date of discharge for the patient, not to exceed 5 years.
|
Measure the frequencies of specific genotyped information on African American patients
Time Frame: Upon patient enrollment, not to exceed 5 years.
|
To develop a repository of information on genotyped African American patients receiving care by a preemptive genotype.
|
Upon patient enrollment, not to exceed 5 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter O'Donnell, MD, University of Chicago
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- IRB17-0890
- U54MD010723 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Information Seeking Behavior
-
London School of Hygiene and Tropical MedicineCompletedInformation Seeking BehaviorUnited Kingdom
-
University of Colorado, DenverCompletedVaccine Hesitancy | Intention | Behavior, Information Seeking
-
Medical University of GrazCompletedHealth Care Utilization | Medication Compliance | Information Seeking BehaviorAustria
-
University of North Carolina, Chapel HillMayo Clinic; National Library of Medicine (NLM); University of Pittsburgh Medical... and other collaboratorsRecruitingCritical Care | Usability | Electronic Health Records | Information Seeking BehaviorUnited States
-
Harvard School of Public Health (HSPH)CompletedEducational Problems | Immunization; Infection | Information Seeking BehaviorNigeria
-
University of AarhusCompletedBreast Neoplasm Female | Decision Making | Mammography Screening | Information Seeking BehaviorDenmark
-
University of AarhusCompletedBreast Cancer Female | Decision Making | Mammography Screening | Information Seeking BehaviorDenmark
-
SangathHarvard Medical School (HMS and HSDM); London School of Hygiene and Tropical...Completed
-
London South Bank UniversityMental Health First Aid EnglandUnknownHelp-Seeking BehaviorUnited Kingdom
-
Vanderbilt UniversityNational Institutes of Health (NIH)CompletedHelp-Seeking Behavior